Meeting
2023 ASCO Annual Meeting
Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
Authors
Mingyuan Sun
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Tianjing, China
Mingyuan Sun , Lugui Qiu , Yongqiang Wei , Jie Jin , Xin Li , Xue Liu , Shaohong Yin , Junyuan Qi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT04984434
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8038)
DOI
10.1200/JCO.2023.41.16_suppl.8038
Abstract #
8038
Poster Bd #
30
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
First Author: Yarong Liu
Poster
2023 ASCO Annual Meeting
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
First Author: Shaji Kumar
Poster
2023 ASCO Annual Meeting
Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
First Author: Mohamad Mohty
Poster
2022 ASCO Annual Meeting
Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1.
First Author: Monique C. Minnema